Overview
To assess the 6-months effects and safety of stellate ganglion block(SGB) for Chronic Migraine (CM) patients who failure to undergo preventive therapy and are seeking a more suitable non-pharmacological therapy.
Description
The investigators aim to investigate whether the stellate ganglion block(SGB) is better than traditional medication treatment and provides medical evidence for the clinical application and promotion of SGB to provide a minimally invasive, safe, and effective treatment for patients with chronic migraine(CM) who failed to receive standardized drug treatment.
Eligibility
Inclusion Criteria:
- Age from 18 to 65 years;
- Diagnosed with CM according to the International Classification of Headache Disorders, 3rd (ICHD-3) criteria [Headache Classification Committee of the International Headache Society (IHS). The International Classification of Headache Disorders, 3rd edition. Cephalalgia. 2018;38:1-211].
- not received prior prophylactic migraine treatment or, due to lack of efficacy or tolerability, had failed or had not been suitable for up to three previous prophylactic treatments from the following: Metoprolol/propranolol, amitriptyline, and flunarizine.
Exclusion Criteria:
- BMI <15 kg/m2 or >35 kg/m2；
- Previous SGB treatment；
- History of other neurological disorders；
- History of severe cardiopulmonary, hepatic or renal dysfunction；
- History of allergies to any of the study drugs；
- Patients with chronic use of opioids；
- Preoperative coagulation abnormalities (activated partial thromboplastin time greater than 1.5 time normal value)；
- Infection or mass near the puncture site；
- Neck anatomic structural changes (caused by radiotherapy or surgery);
- Pregnant or breast feeding;
- Psychological disorders;
- Refusal to sign informed consent.